Hepatocellular Carcinoma: Overcoming Challenges in Disease Management, Clinical Gastroenterology and Hepatology, vol.4, issue.3 ,
DOI : 10.1016/j.cgh.2006.01.001
Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy, Journal of Hepatology, vol.57, issue.6, pp.1251-1258, 2012. ,
DOI : 10.1016/j.jhep.2012.07.018
Serological markers of liver cancer, Best Practice & Research Clinical Gastroenterology, vol.19, issue.1, pp.91-100, 2005. ,
DOI : 10.1016/j.bpg.2004.10.003
Clinical evaluation of free PSA/Total PSA (Prostate-specific Antigen) ratio in the diagnosis of prostate cancer, European Journal of Cancer, vol.33, issue.8, pp.1226-1235, 1997. ,
DOI : 10.1016/S0959-8049(97)00081-6
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer, Lung Cancer, vol.76, issue.2, pp.138-181, 2012. ,
DOI : 10.1016/j.lungcan.2011.11.012
Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer, Cancer Invest, vol.23, pp.338-51, 2005. ,
Human carcinoembryonic antigen, an intercellular adhesion molecule, blocks fusion and differentiation of rat myoblasts, The Journal of Cell Biology, vol.123, issue.2 ,
DOI : 10.1083/jcb.123.2.467
Human carcinoembryonic antigen functions as a general inhibitor of anoikis, Cancer Res, vol.60, pp.3419-3443, 2000. ,
CA 15-3: Uses and limitation as a biomarker for breast cancer, Clinica Chimica Acta, vol.411, issue.23-24, pp.1869-74, 2010. ,
DOI : 10.1016/j.cca.2010.08.039
CA-125 AUC as a new prognostic factor for patients with ovarian cancer, Gynecologic Oncology, vol.97, issue.2, pp.529-563, 2005. ,
DOI : 10.1016/j.ygyno.2005.01.040
CA 19-9 as a Predictor for Response and Survival in Advanced Pancreatic Cancer Patients Treated With Chemoradiotherapy, International Journal of Radiation Oncology*Biology*Physics, vol.73, issue.4, pp.1148-54, 2009. ,
DOI : 10.1016/j.ijrobp.2008.06.1483
Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy, International Journal of Radiation Oncology*Biology*Physics, vol.57, issue.1, pp.90-97, 2003. ,
DOI : 10.1016/S0360-3016(03)00524-8
Usefulness of longitudinal evaluation of Cyfra 21-1 variations in advanced lung cancer monitoring, Lung Cancer, vol.16, issue.2-3, pp.191-202, 1997. ,
DOI : 10.1016/S0169-5002(96)00629-0
Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer, Lung Cancer, vol.74, issue.1, pp.112-119, 2011. ,
DOI : 10.1016/j.lungcan.2011.02.001
Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients, Lung Cancer, vol.31, issue.2-3, pp.221-252, 2001. ,
DOI : 10.1016/S0169-5002(00)00186-0
Comparison of fifteen immunoassays for the measurement of serum MUC-1/CA 15-3 in breast cancer patients Évaluation du dosage de l'ACE, du PSA et de l'AFP sur l'Elecsys? BoehringerMannheim. Transférabilité des résultats entre l'ES 300? et l'Elecsys?. Immuno-analyse &, Clin Chem Lab Med Biologie Spécialisée, vol.4712, pp.985-92138, 1997. ,
Technical and clinical comparison of two fully automated methods for the immunoassay of CA 125 in serum, Journal of Immunological Methods, vol.225, issue.1-2, pp.1-8, 1999. ,
DOI : 10.1016/S0022-1759(99)00023-X
Kryptor - ??valuation finale en situation de routine, Immuno-analyse & Biologie Sp??cialis??e, vol.13, issue.5, pp.307-323, 1998. ,
DOI : 10.1016/S0923-2532(98)80033-1
Evaluation of automated serum des-gamma-carboxyprothrombin (DCP) assays for detecting hepatocellular carcinoma, Clinical Biochemistry, vol.44, issue.17-18, pp.1464-1472, 2011. ,
DOI : 10.1016/j.clinbiochem.2011.08.1144
Evaluation of the UniCel??? DxI 800 Immunoassay Analyzer in Measuring Five Tumor Markers, Yonsei Medical Journal, vol.53, issue.3, pp.557-64, 2012. ,
DOI : 10.3349/ymj.2012.53.3.557
METHOD COMPARISON FOR CA 15-3, CA 19-9, AND CA 125 DETERMINATION USING THE NEW LOCI TECHNIQUE OF DIMENSION VISTA 1500 AND IMMULITE 2000 XPI, Journal of Immunoassay and Immunochemistry, vol.42, issue.6, pp.435-480, 2012. ,
DOI : 10.1309/NBA312W0LANRXYH9
Rare earth cryptates and homogeneous fluoroimmunoassays with human sera Method Comparison and Bias estimation using patient samples, Clin Chem, vol.39, issue.30, pp.1953-1962, 1993. ,
Evaluation of the Performance of Lumipulse G1200 for Tumor Marker Assays Passing H, Bablok. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I, Lab Med Online J Clin Chem Clin Biochem, vol.221, issue.32, pp.131-8709, 1983. ,
Application of the Bland-Altman plot for interpretation of method-comparison studies: a critical investigation of its practice, Clin Chem, vol.482, pp.799-801, 2002. ,
Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring, Clin Chem, vol.45, pp.1695-707, 1999. ,
Tumour marker measurements in the diagnosis and monitoring of breast cancer, Cancer Treatment Reviews, vol.26, issue.2, pp.91-102, 2000. ,
DOI : 10.1053/ctrv.1999.0151
Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA, European Journal of Cancer, vol.40, issue.4, pp.481-487, 2004. ,
DOI : 10.1016/j.ejca.2003.10.015